Onconova On The Edge After Phase III Rigosertib MDS Failure
Switch To Oral Version But Not For MDS
Executive Summary
Onconova’s lead product, rigosertib, has failed in a Phase III study in myelodysplastic syndromes, sending its share price tumbling by 66%.